Pricing Log in Create free account
Friday 6 November 2026 Export TEVA’s income statement to Excel — free account

Teva Pharmaceutical Industries Ltd.

TEVA Healthcare Drug Manufacturers Specialty & Generic

Teva Pharmaceutical Industries Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $17.3 billion, up 4.32% from fiscal 2024.

Revenue
−1.90%
EPS
−47.2%
Free cash flow
−30.3%
Total debt
−0.43%

Quarter to September 2026, against a year earlier

41.73 0.12 −0.29%
Market cap
$48.7B
P/E
92.6×
Fwd P/E
30.7×
Dividend yield
—
F-score
8/9
Altman Z
0.79
Beneish M
−2.35
Dividend safety
52/100
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Teva Pharmaceutical Industries Ltd. (TEVA) SEC filings, changes and red flags

Red flags

  • Officer departure

    Teva Pharmaceutical Industries Ltd. reported the departure of an officer or director

    8-K filed · The filing · sec.gov

  • Restatement

    Teva Pharmaceutical Industries Ltd.’s 10-K corrects an error in previously issued financial statements

    10-K filed · The filing · sec.gov

  • Impairment

    Teva Pharmaceutical Industries Ltd. recorded a goodwill impairment of $280.0 million in fiscal 2024

    10-K filed · The filing · sec.gov

Filings

Form Period Filed What it reports Flags
10-Q Sep 30, 2026 P1I2: 22 added · 14 removed · 122 modified
P2I1A: no material changes, the filing says
8-K Nov 3, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Oct 27, 2026 5.02 Departure or appointment of directors or officers Officer departure
8-K Sep 16, 2026 1.01 Entry into a material definitive agreement; 2.03 Creation of a direct financial obligation; 9.01 Financial statements and exhibits
8-K Sep 14, 2026 8.01 Other events
8-K Sep 9, 2026 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits
8-K Sep 3, 2026 8.01 Other events; 9.01 Financial statements and exhibits
8-K Aug 31, 2026 3.03 Material modification of shareholders' rights; 9.01 Financial statements and exhibits
10-Q Jun 30, 2026 P1I2: 87 added · 11 removed · 107 modified
P2I1A: no material changes, the filing says
8-K Jul 29, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K May 28, 2026 5.07 Submission of matters to a vote of security holders
10-Q Mar 31, 2026
8-K Apr 29, 2026 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
10-K Dec 31, 2025 1: 26 added · 30 removed · 114 modified
1A: 13 added · 15 removed · 90 modified
7: 40 added · 70 removed · 108 modified
8-K Jan 28, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jan 11, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Dec 10, 2025 1.01 Entry into a material definitive agreement; 2.03 Creation of a direct financial obligation; 9.01 Financial statements and exhibits
10-Q Sep 30, 2025
8-K Nov 5, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 30, 2025
8-K Jul 30, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Mar 31, 2025
8-K May 7, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-K Dec 31, 2024 Restatement Impairment
8-K Jan 29, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Sep 30, 2024
8-K Nov 6, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 30, 2024
8-K Jul 31, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K May 8, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jan 31, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Nov 8, 2023 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits

From the company’s filings on sec.gov. Red flags are raised by rules over the filings’ own data and text; they are not investment advice.